Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.67 |
| ▸ | SYK | P43405 | 2/20 | 0.67 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.67 |
| ▸ | FES | P07332 | 1/20 | 0.67 |
| ▸ | FER | P16591 | 1/20 | 0.67 |
| ▸ | FRK | P42685 | 1/20 | 0.67 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.67 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.67 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apilimod SCHEMBL29365634 | 0.80 | PIKFYVE (1.00) | TYK2SYKIRAK4FESFER | |
| Apilimod SCHEMBL426300 | 0.80 | PIKFYVE (1.00) | TYK2SYKIRAK4FESFER | |
| Apilimod SCHEMBL426299 | 0.80 | PIKFYVE (1.00) | TYK2SYKIRAK4FESFER | |
| Apilimod SCHEMBL29387519 | 0.80 | PIKFYVE (1.00) | TYK2SYKIRAK4FESFER | |
| Apilimod SCHEMBL29459498 | 0.80 | PIKFYVE (1.00) | TYK2SYKIRAK4FESFER | |
| SCHEMBL428653 | 0.79 | TYK2 (0.66) | TYK2SYKIRAK4FESFER | |
| SCHEMBL31025329 | 0.79 | TYK2 (1.00) | TYK2SYKIRAK4FESFER | |
| SCHEMBL30273130 | 0.79 | TYK2 (1.00) | TYK2SYKIRAK4FESFER | |
| SCHEMBL1616481 | 0.79 | TYK2 (1.00) | TYK2SYKIRAK4FESFER | |
| SCHEMBL23326603 | 0.79 | TYK2 (0.76) | TYK2SYKIRAK4FESFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-05-08 | — | — | US | claimed |
| US-20210404004-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2021-12-30 | — | — | US | claimed |
| US-10760129-B2 | Th17 differentiation markers for acne and uses thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-09-01 | — | — | US | claimed |
| US-20160326590-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-11-10 | — | — | US | claimed |
| US-20140349866-A1 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-27 | — | — | US | claimed |
| US-20140235475-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| US-20140221231-A1 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-07 | — | — | US | claimed |
| US-20140221648-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2723890-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2723892-A2 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| EP-2723889-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| WO-2013000870-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| WO-2013000869-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| WO-2013000872-A2 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-05-08 | — | — | US | disclosed |
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-05-08 | — | — | US | disclosed |
| US-20210404004-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2021-12-30 | — | — | US | disclosed |
| WO-2013000871-A1 | NEW TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013000870-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013000869-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144107-A1 | USE OF A PIKFYVE INHIBITOR IN COMBINATION WITH IMMUNOTHERAPY | PIKFYVE, LCK, PBK | TYK2 118/4885SYK 111/4885IRAK4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.